Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in MacroGenics between March 7, 2024 to May 9, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 19, 2024 (GLOBE ...

Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) faces a class action lawsuit due to alleged misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1][2]. Group 1 - The class period for the alleged misrepresentations is from March 7, 2024, to May 9, 2024 [1]. - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously stated, resulting in a stock price drop of $11.36 per share [1]. - The Gross Law Firm is encouraging shareholders who purchased MGNX shares during the class period to register for potential lead plaintiff appointment [2]. Group 2 - The deadline for shareholders to register for the class action is September 24, 2024 [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3 - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [3]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [3]. - The firm is recognized nationally for its class action lawsuits [3].

SAN FRANCISCO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): On July 30, 2024, shares in beleaguered pharmaceutical company MacroGenics crashed after the company provided ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=103173&from=3 CLASS PERIOD: March 7, ...

Core Viewpoint - A securities class action lawsuit has been filed against MacroGenics, Inc. for allegedly making false and misleading statements regarding the safety profile of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Maryland on behalf of investors who purchased MacroGenics stock or sold puts between March 7, 2024, and May 9, 2024 [1]. - The lead plaintiff deadline for the lawsuit is September 24, 2024 [1][3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants created a materially misleading impression regarding the safety profile of vobramitamab duocarmazine and the overall data from the Phase 2 TAMARACK study [2]. Group 3: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline or may choose to remain an absent class member [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [3]. Group 4: Firm Information - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4].

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MacroGenics, Inc. (NASDAQ: MGNX) and Vicor Corporation (NASDAQ: VICR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. MacroGenics, Inc. (NASDAQ: MGNX) Class Period: March 7, 2024 ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MacroGenics, Inc. who experienced losses exceeding $100,000 during the specified class period to secure legal counsel before the September 24, 2024 deadline for a securities class action lawsuit [2][3]. Group 1: Class Action Details - The class period for the MacroGenics securities class action is from March 7, 2024, to May 9, 2024, inclusive [2]. - Investors who purchased stock or sold puts during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the court by September 24, 2024 [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The lawsuit alleges that during the class period, MacroGenics made false and misleading statements regarding the safety profile of its drug vobramitamab duocarmazine (vobra duo) in a Phase 2 study for resistant prostate cancer [6]. - The misleading statements created a materially false impression about the drug's safety and the overall data from the Phase 2 TAMARACK study, leading to investor damages when the truth was revealed [6].

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. So what: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=102399&from=4 CLASS PERIOD: March 7, 202 ...